GLP1R and kidney disorder: Thus, meta-analyses published before 2015 [7, 12, 13, 53, 54] did not discuss all the currently available long-acting GLP-1 RAs, while more recent meta-analyses usually targeted semaglutide [8, 9] or focused on emerging outcomes such as cardiovascular or kidney disease [55, 56].